Comparative Efficacy of Low-Molecular-Weight Heparins in Orthopedic Surgery

ABSTRACT

The low-molecular-weight heparins (LMWHs) have been evaluated in the prevention of postoperative thromboembolic disease and have been found to be clinically efficacious and safe.

Studies conducted in similar surgery settings have resulted in significantly different reductions in the incidence of deep-vein thrombosis, making an analysis of grouped studies complex. Only two studies have reported head-to-head comparisons of two different LMWHs and showed no difference in clinical end points between enoxaparin and either reviparin or tinzaparin. Our study at the Aalborg hospital in Denmark, comparing two different dosage regimens of LMWH tinzaparin, supported the conclusions of the head-to-head comparative studies. LMWHs are distinct drug entities that cannot be interchanged at equivalent anti-Xa dosages, and the interpretation of their relative efficacy and safety may be biased by the degree of clinical experience of the individual investigators.

KEYWORD

Orthopedic surgery trials - tinzaparin - enoxaparin - deep-vein thrombosis

REFERENCES

• 1 Planès A, Vochelle N, Ferru J. Enoxaparin low molecular weight heparin: Its use in the prevention of deep venous thrombosis following total hip replacement.  Haemostasis . 1986;  16 152-158
• 2 Planès A, Vochelle N, Mazas F. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.  Thromb Haemost . 1988;  60 407-410
• 3 Planès A, Vochelle N, Mazas F. Double-blind randomized comparative study of enoxaparin and standard heparin in the prevention of thromboembolic disease during insertion of total hip replacement [in French].  Rev Med Interne . 1988;  9 327-333
• 4 Borris L C, Sørensen J V, Lassen M R. Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (enoxaparin) versus dextran 70 in hip arthroplasty.  Thromb Res . 1991;  63 21-28
• 5 Eriksson B I, Wille-Jørgensen P, Kälebo P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
• 6 Kalodiki E Ph, Hoppensteadt D A, Nicolaides A N. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial.  Int Angiol . 1996;  15 162-168
• 7 Planès A, Vochelle N, Fagola M, Bellaud M, and the Reviparin Study Group. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery.  Blood Coagul Fibrinolysis . 1998;  9 499-505
• 8 Warwick D, Harrison J, Glew D. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.  J Bone Joint Surg Am . 1998;  80 1158-1166
• 9 Planès A, Samama M M, Lensing A WA. Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin.  Thromb Haemost . 1999;  81 22-25
• 10 Planès A, Vochelle N, Fagola M. Efficacy and safety of a perioperative enoxaparin regimen in total hip replacement under various anesthesias.  Am J Surg . 1991;  161 525-531
• 11 Planès A, Vochelle N, Darmon J-Y. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery. The French study-Venographic outcome at 35 days.  Chest . 1998;  114 125S-129S
• 12 Lassen M R, Borris L C, Anderson B S. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-The Danish Prolonged Prophylaxis (DaPP) Study.  Thromb Res . 1998;  89 281-287
• 13 Bergqvist D, Benoni G, Bjorgell O. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  N Engl J Med . 1996;  335 696-700
• 14 Dahl O E, Andreassen G, Aspelin T. Prolonged thromboprophylaxis following hip replacement surgery-Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin.  Thromb Haemost . 1997;  77 26-31
• 15 Lassen M R, Borris L C. Low molecular weight heparin for the prevention of deep vein thrombosis following orthopedic surgery.  Curr Opin Pulm Med . 1996;  2 300-304
• 16 Lassen M R, Backs S, Borris L C. Deep-vein thrombosis prophylaxis in orthopedic surgery: Hip surgery.  Semin Thromb Hemost . 1999;  25(suppl 3) 79-82